Clinical Trials Logo

Glycogen Storage Disease Type IB clinical trials

View clinical trials related to Glycogen Storage Disease Type IB.

Filter by:
  • None
  • Page 1

NCT ID: NCT05960617 Recruiting - Clinical trials for Glycogen Storage Disease Type IB

Efficacy and Safety of Empagliflozin in GSD-Ib Patients

Start date: July 15, 2023
Phase: Phase 2
Study type: Interventional

Empagliflozin Treatment of GSD-1b patients

NCT ID: NCT05915910 Terminated - Clinical trials for Glycogen Storage Disease Type IB

Prospective Collection of Biospecimen in Pediatric Patients and Adult Guardians Diagnosed With Glycogen Storage Disease Type 1B (GSD1b)

Start date: April 27, 2023
Phase:
Study type: Observational

The primary objective of this study is to collect whole blood from patients diagnosed with Glycogen storage disease type 1B, which will be used to support the investigation of potential therapies that address the genetic basis of this disease.

NCT ID: NCT04986735 Recruiting - Clinical trials for Glycogen Storage Disease Type IB

Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin

Start date: August 8, 2021
Phase:
Study type: Observational

This is a prospective cohort study of children with GSD1b to evaluate their outcome after using empagliflozin for neutrophil defects.

NCT ID: NCT03655223 Enrolling by invitation - Diabetes Mellitus Clinical Trials

Early Check: Expanded Screening in Newborns

Start date: October 15, 2018
Phase:
Study type: Observational

Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and families who screen positive, and 3) evaluate the Early Check program. The Early Check screening will lead to earlier identification of newborns with rare health conditions in addition to providing important data on the implementation of this model program. Early diagnosis may result in health and development benefits for the newborns. Infants who have newborn screening in North Carolina will be eligible to participate, equating to over 120,000 eligible infants a year. Over 95% of participants are expected to screen negative. Newborns who screen positive and their parents are invited to additional research activities and services. Parents can enroll eligible newborns on the Early Check electronic Research Portal. Screening tests are conducted on residual blood from existing newborn screening dried blood spots. Confirmatory testing is provided free-of-charge for infants who screen positive, and carrier testing is provided to mothers of infants with fragile X. Affected newborns have a physical and developmental evaluation. Their parents have genetic counseling and are invited to participate in surveys and interviews. Ongoing evaluation of the program includes additional parent interviews.

NCT ID: NCT02054832 Completed - Clinical trials for Glycogen Storage Disease Type IA

Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard Versus Modified Uncooked Cornstarch

Start date: November 2013
Phase: N/A
Study type: Observational

The aim of the present study is to determine if there is a change in quality and quantity of sleep perceived by adults and children with GSD and their parents while starting a modified UCCS (Glycosade) to prevent nocturnal hypoglycemia. The investigators also aim to evaluate if there is a change in quality of life perceived by adults and children and their parents with Glycosade.